Tech Company Financing Transactions
Regentis Biomaterials Funding Round
Regentis Biomaterials closed a $15 million Series D investment round on 2/11/2016. Investors included Haisco Pharmaceutical Group, Generali Financial Holdings and Medica Venture Partners.
Transaction Overview
Company Name
Announced On
2/11/2016
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds for conducting a pivotal clinical trial on GelrinC in the United States as required to obtain marketing approval from the FDA.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
12 Ha'ilan St. Northern Industrial Zone P.O.Box 260
Or-Akiva, 3060000
Israel
Or-Akiva, 3060000
Israel
Phone
Website
Email Address
Overview
Regentis Biomaterials is a medical material development company that is focused on commercializing its patent-applied Gelrin Platform Technology for bone, spine and cartilage repair.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alastair Clemow
Chief Scientific Officer
Dror Seliktar
General Manager
Livnat Ben-Zur
VP - R & D
Roni Wechsler
VP - Regulatory Affairs
Brooke Mastrorio
Browse more venture capital transactions:
Prev: 2/11/2016: Gjirafa venture capital transaction
Next: 2/11/2016: InAuth venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs